Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPS1 | P31327 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 3/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 8/20 | 0.48 |
| ▸ | AKR1C2 | P52895 | 8/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | KDM2B | Q8NHM5 | 3/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4839335 | 0.94 | KDM2B (0.50) | CPS1NPC1RAB9ASMN1; SMN2AKR1C3 | |
| SCHEMBL4131191 | 0.90 | ALDH1A1 (0.53) | CPS1NPC1RAB9ASMN1; SMN2AKR1C3 | |
| SCHEMBL7423445 | 0.88 | KDM2B (0.50) | CPS1NPC1RAB9ASMN1; SMN2AKR1C3 | |
| SCHEMBL383820 | 0.82 | ALDH1A1 (0.66) | NPC1RAB9ASMN1; SMN2AKR1C3AKR1C2 | |
| SCHEMBL4126643 | 0.82 | NPC1 (0.53) | CPS1NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL4133619 | 0.82 | MAPT (0.66) | CPS1NPC1RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL12859803 | 0.82 | ALDH1A1 (0.58) | CPS1NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL4128370 | 0.81 | SIGMAR1 (0.57) | KDM4EPOLBALDH1A1MAPT | |
| Benzene SCHEMBL29227606 | 0.81 | ALDH1A1 (0.63) | NPC1RAB9ASMN1; SMN2AKR1C3AKR1C2 | |
| SCHEMBL17682929 | 0.81 | CPS1 (0.59) | CPS1NPC1RAB9ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423030-B2 | 1-amino-phthalazine derivatives, the preparation and the therapeutic use thereof | SANOFI-AVENTIS (FR) | 2008-09-09 | — | — | US | disclosed |
| US-20070099895-A1 | 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-05-03 | — | — | US | disclosed |
| CN-1953972-A | 1-amino-phthalazine derivatives, their preparation and their therapeutic use | SANOFI AVENTIS (FR) | 2007-04-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099895-A1 | 1-AMINO-PHTHALAZINE DERIVATIVES, THE PREPARATION AND THE THERAPEUTIC USE THEREOF | CYP11B2, CYP11B1, GOT2 | CPS1 180/4885NPC1 204/4885RAB9A 3275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.